News

The Integrated COPD Care Initiative in Alabama aims to reduce hospital readmission rates and acute to post-acute care-associated costs in COPD patients. Here are the results so far and insight from one of the program’s leaders.

FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.

Evidence grows that these nonclinical factors have a large influence on patient outcomes. Here’s what hospitals and payers can do about it.

Here are ways healthcare execs can increase cancer awareness efforts.

A Managed Healthcare Executive’s cancer management survey revealed support for the selected use of complementary and alternative medicine. Where do things stand in what some consider a promising treatment area?

COPD is a chronic, progressive disorder that can lead to early death. Here are some ways to help mitigate the risk of developing this debilitating disorder.

The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?

As we look to the next year we can expect to see a few of these challenges settle, while others will continue to make headlines. Here are three things healthcare executives should watch.

In these arrangements, drug companies must partially reimburse insurers if the drug fails to earn its keep. Will COPD drugs be included in such arrangements?

Despite a scolding from President Trump over drug price hikes, drug giant Pfizer announced it will raise the prices of 41 medications in January. That’s 10% of its entire drug portfolio.

FDA approved an autoinjector to treat rheumatoid arthritis and other diseases. 

Here are five things managed care executives should know about the proposed plan.

While some pharma makers have lowered drug prices and Express Scripts is pushing more branded manufacturers to lower list prices with its new National Preferred Flex Formulary, some manufacturers are raising drug prices.

Express Scripts’ new National Preferred Flex Formulary, which offers lower list prices on certain branded drugs, is a novel way to encourage pharma makers to lower prices.

Coming up with the benchmarks for measuring and rewarding quality and efficiency and finding the right provider partner are only part of the battle. Don’t forget about compliance with state and federal requirements. 

Frail patients are a  forgotten patient group-here’s how they were left behind and what can be done about it.

The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.

Despite concerns about a new opioid that is reportedly 1,000 times more powerful than morphine, FDA recently approved the new painkiller.

Certain groups expressed “deep concern” over FDA allowing an OTC asthma inhaler to be sold again after it was removed from the market 7 years ago. Here’s why.

It’s the hot new skill showing up across the resumes and job postings-but what does if have to do with healthcare?

This comprehensive, pay-for-performance approach drives clinical quality and affordability.

Here is the one surprising thing that improves patients’ ability to effectively manage their own health.

Biosimilar agents can help healthcare organizations offer patients more options for their care. So, what’s stopping payers from immediately adding them to their formularies?

As healthcare organizations move toward value-based models of reimbursement, high drug prices can sometimes get in the way of optimal care. Here are three ways that biosimilars may help.

A new cost analysis study presented at Psych Congress 2018, highlights the substantial economic burden among U.S. veterans with treatment-resistant depression and what can be done about it.

Four things you need to know about the Trump Administration’s proposed regs.

The much-anticipated 2018 midterm elections are over, but the effects on healthcare are lasting. What’s next?